{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:02:26Z","timestamp":1648684946071},"reference-count":42,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T00:00:00Z","timestamp":1334016000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>Reduced vancomycin susceptibility (RVS) may lead to poor clinical outcomes in <jats:italic>Staphylococcus aureus<\/jats:italic> bacteraemia. We conducted a cohort study of 392 patients with <jats:italic>S. aureus<\/jats:italic> bacteraemia within a university health system. The association between RVS, as defined by both Etest [vancomycin minimum inhibitory concentration (MIC) &gt;1\u00b70\u00a0\u03bcg\/ml] and broth microdilution (vancomycin MIC \u2a7e1\u00b70\u00a0\u03bcg\/ml), and patient and clinical variables were evaluated to create separate predictive models for RVS. In total, 134 (34\u00b72%) and 73 (18\u00b76%) patients had <jats:italic>S. aureus<\/jats:italic> isolates with RVS by Etest and broth microdilution, respectively. The final model for RVS by Etest included methicillin resistance [odds ratio (OR) 1\u00b751, 95% confidence interval (CI) 0\u00b797\u20132\u00b734], non-white race (OR 0\u00b767, 95% CI 0\u00b742\u20131\u00b707), healthcare-associated infection (OR 0\u00b756, 95% CI 0\u00b732\u20130\u00b796), and receipt of any antimicrobial therapy \u2a7d30 days prior to the culture date (OR 3\u00b706, 95% CI 1\u00b772\u20135\u00b744). The final model for RVS by broth microdilution included methicillin resistance (OR 2\u00b745, 95% CI 1\u00b742\u20134\u00b724), admission through the emergency department (OR 0\u00b754, 95% CI 0\u00b732\u20130\u00b792), presence of an intravascular device (OR 2\u00b724, 95% CI 1\u00b730\u20133\u00b786), and malignancy (OR 0\u00b751, 95% CI 0\u00b726\u20131\u00b700). The availability of an easy and rapid clinical prediction rule for early identification of RVS can be used to help guide the timely and individualized management of these serious infections.<\/jats:p>","DOI":"10.1017\/s0950268812000295","type":"journal-article","created":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T08:37:10Z","timestamp":1334047030000},"page":"165-173","source":"Crossref","is-referenced-by-count":2,"title":["Derivation and validation of clinical prediction rules for reduced vancomycin susceptibility in <i>Staphylococcus aureus<\/i> bacteraemia"],"prefix":"10.1017","volume":"141","author":[{"given":"J. H.","family":"HAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. B.","family":"BILKER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. H.","family":"EDELSTEIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. B.","family":"MASCITTI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"LAUTENBACH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2012,4,10]]},"reference":[{"key":"S0950268812000295_ref26","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Informational supplement M100-S18. Wayne, PA, CLSI, 2008."},{"key":"S0950268812000295_ref22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir118"},{"key":"S0950268812000295_ref17","doi-asserted-by":"crossref","unstructured":"Aguado JM , High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia. Emerging Infectious Diseases 2011. (http:\/\/www.cdc.gov\/EID\/content\/17\/6\/1099.htm). Accessed 9 May 2011.","DOI":"10.3201\/eid\/1706.101037"},{"key":"S0950268812000295_ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-159"},{"key":"S0950268812000295_ref10","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.19.2138"},{"key":"S0950268812000295_ref9","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilutional antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7. Wayne, PA: CLSI, 2007."},{"key":"S0950268812000295_ref4","first-page":"765","article-title":"Staphylococcus aureus with reduced susceptibility to vancomycin \u2013 United States, 1997","volume":"46","year":"1997","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"S0950268812000295_ref3","doi-asserted-by":"publisher","DOI":"10.1086\/502522"},{"key":"S0950268812000295_ref35","volume-title":"An Introduction to the Bootstrap","author":"Efron","year":"1998"},{"key":"S0950268812000295_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.11.029"},{"key":"S0950268812000295_ref13","doi-asserted-by":"publisher","DOI":"10.1086\/421092"},{"key":"S0950268812000295_ref14","doi-asserted-by":"publisher","DOI":"10.1086\/524667"},{"key":"S0950268812000295_ref34","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4"},{"key":"S0950268812000295_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.10.029"},{"key":"S0950268812000295_ref1","doi-asserted-by":"publisher","DOI":"10.1086\/591861"},{"key":"S0950268812000295_ref20","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir270"},{"key":"S0950268812000295_ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.15.1763"},{"key":"S0950268812000295_ref21","doi-asserted-by":"publisher","DOI":"10.1086\/597359"},{"key":"S0950268812000295_ref6","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01388-06"},{"key":"S0950268812000295_ref30","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.169.4.379"},{"key":"S0950268812000295_ref19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir124"},{"key":"S0950268812000295_ref27","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A9. Wayne, PA, CLSI, 2006."},{"key":"S0950268812000295_ref24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00093-09"},{"key":"S0950268812000295_ref8","unstructured":"Etest technical manual. AB Biodisk (http:\/\/www.abbiodisk.com\/bd_litt_etm.html). Accessed 5 November 2011."},{"key":"S0950268812000295_ref38","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir764"},{"key":"S0950268812000295_ref5","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm258"},{"key":"S0950268812000295_ref15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00113-08"},{"key":"S0950268812000295_ref41","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2295-2297.2004"},{"key":"S0950268812000295_ref37","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/663708","article-title":"Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia","volume":"33","author":"Anthony","year":"2012","journal-title":"Infection Control and Hospital Epidemiology"},{"key":"S0950268812000295_ref31","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"S0950268812000295_ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00341-9"},{"key":"S0950268812000295_ref39","doi-asserted-by":"publisher","DOI":"10.1086\/375057"},{"key":"S0950268812000295_ref11","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.6.2398-2402.2004"},{"key":"S0950268812000295_ref40","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq373"},{"key":"S0950268812000295_ref42","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3462-1"},{"key":"S0950268812000295_ref12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00939-06"},{"key":"S0950268812000295_ref33","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"1989"},{"key":"S0950268812000295_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.05.007"},{"key":"S0950268812000295_ref18","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq050"},{"key":"S0950268812000295_ref32","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115101"},{"key":"S0950268812000295_ref28","doi-asserted-by":"publisher","DOI":"10.1086\/502493"},{"key":"S0950268812000295_ref25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00269-10"}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268812000295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T16:30:21Z","timestamp":1556123421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268812000295\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,10]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0950268812000295"],"URL":"https:\/\/doi.org\/10.1017\/s0950268812000295","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,10]]}}}